MSI-H/dMMR + TMB-L	Pancreatic Cancer	MSI-H/dMMR + TMB-L	Pancreatic Cancer	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3
MSI-H/dMMR + TMB-L	Cholangiocarcinoma	MSI-H/dMMR + TMB-L	Cholangiocarcinoma	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3
MSI-H/dMMR + TMB-L	Colorectal Cancer	MSI-H/dMMR + TMB-L	Colorectal Cancer	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3
MSI-H/dMMR + TMB-L	Gastric Cancer	MSI-H/dMMR + TMB-L	Gastric Cancer	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3
MSI-H/dMMR + TMB-L	Small Intestinal Carcinoma	MSI-H/dMMR + TMB-L	Small Intestinal Carcinoma	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3

MSI-H/dMMR + TMB-L

Associations